KPG-121 is under clinical development by Kangpu Biopharmaceuticals and currently in Phase I for Metastatic Castration-Resistant Prostate Cancer (mCRPC). According to GlobalData, Phase I drugs for Metastatic Castration-Resistant Prostate Cancer (mCRPC) have an 88% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how KPG-121’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
KPG-121 overview
KPG-121 is under development for the treatment of metastatic castration-resistant prostate cancer, acute myelocytic leukemia and myelodysplastic syndrome. The drug candidate is administered through oral route formulated as capsules. It is a novel generation of lenalidomide and acts by targeting cereblon (a component of a cullin ring E3 ubiquitin ligase enzyme complex).
Kangpu Biopharmaceuticals overview
Kangpu Biopharmaceuticals (Kangpu) focused on the discovery and development of innovative small molecules for the treatment of solid tumors, hematological malignancies, auto-immune diseases that developed X-Synergy, a proprietary drug combination technology. Kangpu is headquartered in Shanghai, China.
For a complete picture of KPG-121’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.